HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells

Abstract Background Chronic myeloid leukemia is associated with a more favorable prognosis following treatment with BCR::ABL1 tyrosine kinase inhibitors (TKIs). Nonetheless, about 40% of affected individuals with CML display resistance or intolerance towards BCR::ABL1 TKIs. Heat shock protein 90 (HS...

Full description

Saved in:
Bibliographic Details
Main Authors: Masanobu Tsubaki, Taira Matsuo, Rie Komori, Noriaki Nagai, Tetsushi Yamamoto, Shozo Nishida
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Online Access:https://doi.org/10.1186/s43094-025-00767-w
Tags: Add Tag
No Tags, Be the first to tag this record!